CMV ICP8 Antibodies

Santa Cruz Biotechnology delivers a wide array of monoclonal CMV ICP8 antibodies for research focused on understanding the cytomegalovirus (CMV) immediate-early protein ICP8. Monoclonal CMV ICP8 antibodies are compatible with multiple experimental techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CMV ICP8 plays an essential role in viral DNA replication and serves as a key component in the viral life cycle, making it a significant target for studying CMV pathogenesis and potential therapeutic interventions. Understanding CMV ICP8 function provides valuable insights into viral behavior and host interactions, which is crucial for developing effective antiviral strategies. Research on CMV ICP8 is particularly relevant in immunocompromised patients, where CMV infections can lead to severe complications. Monoclonal CMV ICP8 antibodies enable detailed investigation of viral protein localization, expression patterns, and molecular interactions. Researchers utilizing monoclonal CMV ICP8 antibodies from Santa Cruz Biotechnology contribute to advancing our understanding of viral pathogenesis and the development of targeted therapeutic strategies.